CAR-M therapy LIB820 may deplete disease-driving B-cells in MS and other autoimmune diseases without severe side effects, new ...
ImmunityBio (IBRX) shares gained on Friday after the cancer drug developer announced the successful conclusion of two manufacturing engineering programs designed to validate its Cytokine-Enriched NK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results